Lifebit, a global leader in genomics and health data software, announces its expansion into Asia Pacific and Japan (APJ) with its new regional operation headquartered in Singapore. The R&D centre established by Lifebit in Singapore will actively contribute to other recent collaborations within the APJ region.

These R&D efforts in collaboration with Synapxe, Singapore’s national HealthTech agency, will serve to advance precision medicine initiatives across the APJ region. It will enable Lifebit to support vital precision medicine research in the region with its patented federated technology platform for genomics and biomedical data. Singapore stands out as the most rapidly expanding market in Asia, backed by a robust governmental dedication to fostering precision medicine research and innovation through the utilisation of genomic and clinical data.  

Dr Maria Dunford, CEO of Lifebit, said “We are delighted to be expanding our operations with a new regional headquarters in Singapore. Our presence here presents a unique opportunity to support the diverse data needs of healthcare organisations, research institutes and pharma companies in the region.

“We are currently implementing our genomic data analytics solution into TRUST to support broader precision medicine research in Singapore, and the wider APJ region. We look forward to working in partnership with additional organisations who, like us, are pushing the boundaries to solve the most challenging problems in genomics and precision medicine.”

Andy Ta, Chief Data Officer and Director, Data Analytics & AI of Synapxe, said “Through our collaboration with Lifebit, we look forward to advancing the use of research and clinical insights using clinico-genomic data for precision medicine. By doing so, we hope to accelerate the translation into clinical workflows, in a manner that will make a significant impact to improving healthcare for Singaporeans.”

Lifebit’s emohasising on making biomedical data accessable to curing diseases. Its expansion into APJ builds on the growth of Lifebit, with new partnerships announced in the USA, Central and South America, and Europe over the past 12 months.

In 2022 Lifebit raised a $60 million Series B funding round, led by global investment firm Tiger Global Management. Its pioneering technology makes vital biomedical data findable, and usable, through a highly secure research environment. Lifebit’s suite of AI-powered, end-to-end federated software solutions can enable faster data insights, accelerate drug discovery pipelines, and improve clinical trials interpretation success.